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Introduction
Thin-walled lymphatic capillaries collect interstitial fluid (lymph) 
and transport it via collecting lymphatic vessels to the thoracic 
duct, which in turn drains into the subclavian vein (1). Improper 
drainage of this extravasated protein-rich fluid from the tissues 
causes it to accumulate, resulting in lymphedema (2). Intraluminal 
lymphatic valves within the collecting lymphatic vessels and bicus-
pid lymphovenous valves ensure anterograde lymph drainage 
into the venous circulation (3). Additionally, these valves prevent 
backflow of venous blood into the thoracic and right lymphatic 
ducts, effectively separating the blood and lymphatic systems (4, 
5). Platelet-mediated intervascular hemostasis also functions with 
lymphovenous valves to maintain this separation throughout life 
(4). Developmental or functional defects in these valves can cause 
both primary and secondary lymphedema (6, 7).
Lymphatic endothelial cells (LECs), the building blocks of the 
mammalian lymphatic vasculature, experience shear stress gen-
erated by the cephalad movement of lymphatic fluid (8). Recent 
evidence demonstrates that this oscillatory lymph flow–mediated 
shear stress initiates stepwise morphological and molecular 
changes within LECs that lead to the formation of lymphatic 
valves (8–11). Specifically, oscillatory shear stress (OSS) induces 
the expression of genes, including GATA2, FOXC2, GJA4, and 
ITGA9, in LECs that are important for lymphatic valve develop-
ment (9, 10, 12). GATA2, an upstream transcriptional regulator of 
FOXC2, PROX1, GJA4, and ITGA9, is important for blood-lymph 
separation and the development of lymphovenous and lymphatic 
valves (9, 10, 13, 14). Despite this evidence, the mechanisms driv-
ing OSS-mediated GATA2 expression during lymphatic valve 
development remain elusive.
GATA2 belongs to an evolutionarily conserved family of zinc 
finger transcription factors that play important roles in diverse 
developmental programs (15, 16). Monoallelic missense mutations 
and intragenic microdeletions in human GATA2 cause Emberger 
syndrome, characterized by primary lymphedema with a predis-
position to myelodysplastic syndrome or acute myeloid leuke-
mia (17–19). Moreover, 2  recurrent mutations that cause reduced 
GATA2 expression (c.1017+512del28 and c.1017+572C>T) within 
a highly conserved 167-bp intragenic enhancer of intron 5 of 
GATA2 have been found in patients with primary lymphedema 
(20–22). Recent studies in transgenic mice demonstrate that this 
intragenic enhancer confers GATA2 expression specifically within 
endothelial cells of the lymphatic, cardiac, and vascular systems 
(14, 23). Indeed, murine embryos lacking this Gata2 intragenic 
enhancer have  reduced Gata2 expression and phenocopy the 
endothelial knockout of Gata2 (24). Thus, there is strong evidence 
that reduced GATA2 expression leads to lymphedema (10, 20, 25).
Broadly, enhancers function as cis-regulatory elements 
controlling gene expression in a spatiotemporal and cell type– 
specific manner (26). Enhancer element activation is dependent 
on recruitment of specific transcription factors, coactivators, chro-
matin remodelers, and histone-modifying enzymes (27). The lat-
ter establish histone marks that often serve to recruit a multitude 
of transcription factors and cofactors to gene regulatory elements 
(26, 28). In addition, active enhancers show enrichment of Lys-27 
acetylation on histone H3 (H3K27ac) and occupancy of the his-
tone acetyltransferase EP300 (29–31). While the complex regu-
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in transcriptional repression (32). On the basis of their catalytic 
mechanism and sequence homology, HDACs are classified into 5 
subfamilies: class I (Hdac1, 2, 3, and 8), class IIa (Hdac4, 5, 7, and 
9), class IIb (Hdac6 and 10), class III (Sirt1, 2, 3, 4, 5, 6, and 7), and 
class IV (Hdac11) (33). Among HDACs, global loss of class I HDACs 
in mice causes embryonic or neonatal lethality, suggesting that 
these enzymes play pivotal roles in development (34–38). Recent 
studies from our laboratory and others have identified unique and 
lation of enhancer elements is starting to be defined, the role of 
histone-modifying factors in regulating the transcriptional activity 
of the Gata2 intragenic enhancer remains unknown.
Two opposing classes of histone-modifying enzymes, histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), 
regulate the acetylation state of histones within an enhancer (32). 
Acetylation by HATs is generally associated with transcriptional 
activation, while HDAC-mediated deacetylation usually results 
Figure 1. Lymphatic endothelial Hdac3 regulates blood-lymphatic separation. (A) Dissected E12.5 and E14.5 Hdac3TekKO embryos. Green arrow shows ectatic 
superficial vessels; black arrow shows pooling of blood in the jugular region; red arrow shows swelling. (B and C) Neonatal (P6) Hdac3Cdh5KO mice (B) and 
P0 Hdac3Lyve1KO mice (C) had abnormal blood-filled dermal vessels (green arrows) compared with controls. (D–F) H&E and coimmunofluorescence staining 
for Lyve1 (lymphatic marker, red) and Emcn (venous marker, green) shows blood-filled (green arrows) dermal lymphatic vessels in E14.5 Hdac3TekKO murine 
embryos (D) and blood-filled dermal (E) and intestinal lymphatic vessels (F) in P6 Hdac3Cdh5KO neonates (E and F). White arrows show lymphatic vessels. (G) 
Dissected intestine of control and Hdac3Cdh5KO P6 neonates. White, red, and blue arrows indicate lymphatic, arterial, and venous vessels, respectively; black 
arrow shows a mesenteric lymph node; green arrows show blood-filled lymphatic vessels and a mesenteric lymph node in Hdac3Cdh5KO P6 neonates. (H and 
I) P8 Hdac3Cdh5KO (H) and P0 Hdac3Lyve1KO (I) hearts show ectatic and hemorrhagic superficial vessels (green arrows). H&E and coimmunofluorescence staining 
for Lyve1 (lymphatic marker, red) and Emcn (venous marker, green) shows blood-filled (green arrows) cardiac lymphatic vessels in P8 Hdac3Cdh5KO (H) and P0 
Hdac3Lyve1KO (I) murine hearts. White arrows show lymphatic vessels. Scale bars: 100 μm. A, artery; LV, lymphatic vessel; MLN, mesenteric lymph node; V, vein. 
See also Supplemental Figures 1–4 and Supplemental Tables 1–5. 
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Here, we show that endothelial Hdac3, but not Hdac1 or Hdac2, 
is important for blood lymphatic separation. Mice lacking endothe-
lial Hdac3 demonstrate congenital lymphedema due to defective 
lymphovenous and intraluminal lymphatic valve development. 
Our studies reveal that Hdac3-mediated epigenetic regulation of 
an OSS-dependent Gata2 intragenic enhancer orchestrates lym-
phatic valve development and establishes blood-lymph separation.
Results
Lymphatic endothelial Hdac3 regulates blood-lymph separation. 
Hdac3 is ubiquitously expressed, including within LECs of devel-
oping lymphovenous valves, mesenteric lymphatic vessels and 
valves, heart, and peripheral lymphatic vessels (Supplemen-
tal Figure 1, A–G; supplemental material available online with 
tissue-specific functions of ubiquitously expressed class I HDACs 
during cardiac and craniofacial development (36, 39–42). Class 
I HDACs lack intrinsic DNA-binding domains and are instead 
recruited to the chromatin in a signal-dependent manner via their 
interactions with multiple protein nuclear complexes, transcrip-
tion factors, and cofactors (32). Contrary to previous assump-
tions, emerging data from genome-wide mapping reveal that the 
majority of HATs and class I HDACs are recruited to promoter and 
enhancer regions of actively transcribed genes with acetylated 
histones (43). Among class I HDACs, Hdac3 mainly occupies 
intragenic and intergenic regions, including enhancers marked 
by H3K27ac and EP300 enrichment (44–47). Despite advances 
in understanding the developmental roles of class I HDACs, their 
role in vascular and lymphatic development remains undefined.
Figure 2. Hdac3 is an important regulator of lymphovenous valve development. (A–C) Schematic model depicting normal anatomy of a developing  
murine lymphovenous valve (A, black arrow) in transverse (B) and coronal (C) planes. (D) Transverse sections of E14.5 Hdac3TekKO embryos revealed blood-
filled lymph sacs (orange arrows) lined by lymphatic (Lyve1 immunostaining [red], white arrows), but not venous (Emcn immunostaining, green), endothe-
lial cells compared with that seen in controls. (E) Dissected P5 Hdac3Cdh5KO mice had a blood-filled thoracic duct (green arrow) compared with a chyle-filled 
thoracic duct in control mice (black arrow). (F) H&E-stained coronal sections of an E13.5 Hdac3TekKO embryo revealed a blood-filled lymph sac (orange arrow) 
and disrupted morphology of the lymphovenous valves (green arrows) compared with controls (yellow arrows). Immunofluorescence staining for podoplanin 
(Pdpn) (green) and Lyve1 (red) showed overlapping expression (yellow) in E13.5 LVVs. Orange arrow indicates a blood-filled lymph sac. (G and H) H&E-stained 
coronal sections of E17.5 Hdac3Cdh5KO (G) and Hdac3Lyve1KO (H) embryos revealed disrupted morphology of the lymphovenous valves (blue arrows) compared 
with controls (green arrows). Orange arrow shows a blood-filled lymph sac. Lyve1 (red) was expressed in E17.5 murine lymphovenous valves (G and H). Emcn 
(green, venous marker) was used as a negative control for lymphovenous valves (H). IJV, internal jugular vein; LS, lymph sac; LVV, lymphovenous valve; SVC, 
superior vena cava; TD, thoracic duct. Scale bars: 100 μm and 50 μm (F, bottom panels, G, and H). See also Supplemental Figure 5 and Supplemental Table 5.
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in endothelial cells using Hdac3fl/fl mice and 3 Cre lines: Tek-Cre 
(Hdac3TekKO), Cdh5-Cre (Hdac3Cdh5KO), and Lyve1-Cre (Hdac3Lyve1KO) 
(Supplemental Figure 1, A, D, and G) (50–52). Hdac3TekKO mice were 
identified until E14.5 but not at birth (P0), indicating complete 
this article; https://doi.org/10.1172/JCI92852DS1) (39, 40, 48, 
49). Germline deletion of Hdac3 results in embryonic lethality 
before E9.5 (34, 37). To determine the function of Hdac3 in the 
developing blood and lymphatic vasculature, we deleted Hdac3 
Figure 3. Hdac3 deficiency causes impaired lymphatic drainage and anomalous lymphatic valve development in mesenteric lymphatic vessels. (A and B) 
Evans blue dye injection into the left hind paw (A and B, white arrows) of P5 Hdac3Cdh5KO mice showed reflux (retrograde flow) into the tail, right hind limb, and 
abdomen (A and B, red arrows) compared with an absence of reflux in the control mice (black arrows). Original magnification ×2.5. (C and D) P5 Hdac3Cdh5KO mice 
showed Evans blue dye reflux (red arrows) into dermal lymph vessels and mesenteric lymph nodes compared with control mice (dotted line, black arrows). Original 
magnification ×3. (E) Control P5 mice showed normal unidirectional cephalad drainage restricted to the thoracic duct (black arrow). Hdac3Cdh5KO mice exhibited 
reflux into the intercostal lymphatics lateral to the thoracic duct in the thoracoepigastric region (red arrows) and reduced drainage into the thoracic duct (green 
arrow). (F) Coimmunofluorescence staining for Lyve1 (green) and smooth muscle actin (SMA) (red) showed abnormal smooth muscle recruitment (white arrows) 
to blood-filled dermal lymphatic capillaries in P6 Hdac3Cdh5KO mice compared with controls. (G) Quantitation of lymphatic valve territories in E17.5 Hdac3Lyve1KO 
mesenteric lymphatic vessels. The P value was determined by unpaired Student’s t test. (H–J) Whole-mount coimmunofluorescence staining of Hdac3Lyve1KO (H and 
I) and Hdac3Cdh5KO (J) mesenteric lymphatic vessels showed a lack of Prox1-expressing (red) lymphatic valves in Pecam1+ (green) lymphatic vessels (yellow arrows) 
compared with controls (white arrows). (K and L) Whole-mount coimmunofluorescence staining of Hdac3Lyve1KO (K) and Hdac3Cdh5KO (L) mesenteric lymphatic vessels 
showed a lack of Itga9-expressing (green) lymphatic valves in Prox1+ (red) lymphatic vessels (yellow arrows) compared with controls (white arrows). (M and N) 
Whole-mount coimmunofluorescence staining of Hdac3Lyve1KO (M) and Hdac3Cdh5KO (N) mesenteric lymphatic vessels showed excessive SMA (red) coverage (yellow 
arrows) compared with controls (white arrows). Vegfr3 (green) was used as a lymphatic vessel marker. Data represent the mean ± SEM and are representative of 3 
independent experiments. Sub-stacks of Z-stack images are presented in H–N. Scale bars: 100 μm (F) and 1 μm (H–N). See also Supplemental Figure 6.
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between P5 and P6 and in heart at P0 (Figure 1, F–H). Similarly, 
Hdac3Lyve1KO neonates had blood-filled cardiac lymphatic vessels 
at P0 (Figure 1I). We observed no apparent structural defects in 
Hdac3Cdh5KO or Hdac3Lyve1KO hearts (Supplemental Figure 2, A and 
B). Among class I HDACs, murine embryos lacking Hdac1 or 
Hdac2 in the endothelial cells (Hdac1TekKO or Hdac2TekKO) appeared 
normal, with complete segregation of blood and lymphatic vas-
culature (Supplemental Figure 3, A and B). To determine whether 
ubiquitously expressed Hdac3 functions within platelets to main-
tain separation of the venous and lymphatic vasculature during 
development, we deleted Hdac3 in the platelets using PF4-iCre 
(Hdac3PF4KO) (53). Hdac3PF4KO neonatal mice were viable, appeared 
embryonic lethality (Supplemental Tables 1 and 2). Hdac3TekKO 
embryos showed ectatic superficial vessels, pooling of blood in 
the jugular region, and severe edema at E14.5 compared with that 
seen in E12.5 embryos (Figure 1A). Hdac3Cdh5KO and Hdac3Lyve1KO 
neonates revealed similar ectatic dermal vessels at P6 and P0 and 
neonatal lethality at P9 and P0, respectively (Figure 1, B and C, 
and Supplemental Tables 3 and 4). Endothelial cells lining blood-
filled superficial vessels in Hdac3TekKO embryos and Hdac3Cdh5KO 
neonates were positive for the lymphatic marker Lyve1, but neg-
ative for the venous marker Emcn, suggesting lymphatic identity 
(Figure 1, D and E). Additionally, Hdac3Cdh5KO neonates exhib-
ited blood-filled lymphatic vessels in intestine and mesentery 
Figure 4. Hdac3 regulates Gata2 
and its target gene expression in 
developing lymphatic valves and 
lymphovenous valves. (A) Tran-
scripts for Gata2, Foxc2, Gja4, and 
Itga9 were detected by ChIP-qPCR 
in control and Hdac3Cdh5KO mesenteric 
lymphatic vessels dissected from P5 
mice. (B) Whole-mount immuno-
fluorescence staining of Hdac3Cdh5KO 
mesenteric lymphatic vessels iden-
tified reduced Prox1 (red) expression 
in Vegfr3+ (red) LECs (red arrows) 
compared with controls (white 
arrows). (C) Transcripts for Gata2 and 
Foxc2 were detected by ChIP-qPCR 
in control and Hdac3Lyve1KO mesenteric 
lymphatic vessels dissected from P0 
mice. (D) Transcripts for Gata2, Foxc2, 
Gja4, and Itga9 were detected by 
ChIP-qPCR in laser-captured control 
and Hdac3TekKO lymphovenous valves 
from E13.5 embryos. (E–G) Immunos-
taining of E13.5 Hdac3TekKO lym-
phovenous valves revealed reduced 
Gata2 (E, red arrows), Foxc2 (F, red 
arrows), and Prox1 (G, red arrows) 
expression compared with controls 
(black arrows). LV, lymphatic valve; R, 
rib. Data represent the mean ± SEM 
and are representative of 3 inde-
pendent experiments. P values were 
determined by Student’s t test. Scale 
bars: 500 μm. See also Supplemental 
Figure 7.
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normal, and displayed complete blood-lymph separation (Supple-
mental Figure 4, A–S). Together, these results suggest that Hdac3 
functions in LECs to regulate separation of the blood and lym-
phatic systems during development.
Hdac3 regulates lymphovenous valve development. Bicuspid 
lymphovenous valves, located at the thoracic duct–subclavian 
vein junction and right lymphatic duct–subclavian vein junc-
tion, maintain the separation between the high-pressure vas-
cular system and the low-pressure lymphatic system (3–5). To 
investigate blood pooling in the jugular region of the embryos 
lacking endothelial Hdac3 (Figure 1B), we examined the mor-
phology of developing lymphovenous valves and lymph sac in 
transverse and coronal sections (Figure 2, A–C). Embryos lack-
ing endothelial Hdac3 displayed abnormal blood-filled lymph 
sacs at various developmental stages (Figure 2, D, F, and G, and 
Supplemental Figure 5). Endothelial cells lining blood-filled 
lymph sacs in Hdac3-null embryos revealed similar expression 
levels of Lyve1 or Vegfr3 (Figure 2D and Supplemental Fig-
ure 5). Consistent with this observation, the thoracic duct in 
Hdac3Cdh5KO neonates showed infiltration of blood into the nor-
mally lymph-filled duct, suggesting a functional lymphove-
nous valve defect (Figure 2E). Indeed, Hdac3TekKO, Hdac3Cdh5KO, 
and Hdac3Lyve1KO embryos displayed shortened lymphovenous 
valve leaflets with defective perpendicular alignment to the 
flow direction (Figure 2, F–H).
Hdac3 regulates proper lymphatic transport and mesenteric 
lymphatic valve maturation. Dysfunctional intraluminal lymphat-
ic valves in collecting lymphatic vessels impede the ability of 
the lymphatic system to effectively transport lymph, leading to 
lymphedema (6, 7). To study the lymph transport in Hdac3Cdh5KO 
neonates, we determined retrograde lymphatic flow reflux using 
Evans blue dye (Figure 3, A–E). Hdac3Cdh5KO neonates had abnormal 
retrograde flow of Evans blue dye into the tail, right hind limb, abdo-
men, dermal lymphatic vessels, mesenteric lymphatic vessels, and 
mesenteric lymph nodes (Figure 3, A–D). We also observed Evans 
blue dye in intercostal lymphatics lateral to the thoracic duct in the 
thoracoepigastric region, coupled with reduced contrast drainage 
into the thoracic duct in Hdac3Cdh5KO neonates compared with the 
control (Figure 3E), suggesting a severe impairment of lymph trans-
port. Consistent with this observation, Lyve1+ dermal lymphatic 
capillaries revealed anomalous recruitment of smooth muscle 
cells in P6 Hdac3Cdh5KO neonates (Figure 3F). Additionally, Hdac3- 
deficient mesenteric lymphatic vessels showed immature and 
reduced numbers of lymphatic valves at various stages of develop-
Figure 5. Hdac3 regulates oscillatory shear stress–mediated activation of the Gata2 intragenic enhancer. (A) Schematic of in vitro OSS assay. (B) 
Transcripts for Gata2 were detected by ChIP-qPCR in scrambled shRNA– (Sc-shRNA) or Hdac3 shRNA–infected LECs subjected to static or OSS condi-
tions and coinfected with GFP, HDAC3, HDAC3H134A,H135A, or HDAC3HEBI lentiviruses. (C) Schematics of luciferase reporter vectors composed of WT (168 bp), 
c.1017+512del28 (28-bp deletion, green box, 140 bp), and the c.1017+572C>T point mutation (blue box) GATA2 intragenic enhancer. (D) A dual luciferase 
assay was performed in LECs transfected with WT, c.1017+512del28, or the c.1017+572C>T point mutation GATA2  intragenic enhancer luciferase reporter 
and subjected to static or OSS conditions. Induction is represented as a ratio of firefly to Renilla luciferase activity. (E) Scramble shRNA– or Hdac3 shRNA–
infected LECs, cotransfected with the WT GATA2 intragenic enhancer luciferase reporter, were subjected to static or OSS conditions. Induction is repre-
sented as a ratio of firefly to Renilla luciferase activity. Data represent the mean ± SEM and are representative of 3 independent experiments. P values 
were determined by Student’s t test (B and D) or by 1-way ANOVA with Sidak’s multiple comparisons test (E). See also Supplemental Figures 8 and 9.
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ment (Figure 3, G–N, and Supplemental Figure 6, A–D). Prox1 and 
Pecam1 whole-mount immunofluorescence costaining analyses 
revealed fewer and disorganized Prox1Hi LEC clusters in Hdac3Cdh5KO 
and Hdac3Lyve1KO lymphatic vessels (Figure 3, H–J, and Supplemen-
tal Figure 6, A–D). Hdac3Cdh5KO and Hdac3Lyve1KO lymphatic vessels 
showed reduced integrin-α9 expression within lymphatic valve sites 
(Figure 3, K and L). In addition, Hdac3-deficient lymphatic collect-
ing vessels exhibited excessive smooth muscle cell coverage com-
pared with controls (Figure 3, M and N).
Hdac3 regulates Gata2 expression in developing lymphovenous 
and lymphatic valves. Transcriptional analysis of mesenteric 
lymphatic vessels dissected from Hdac3Cdh5KO neonates revealed 
downregulation of genes required for lymphatic valve develop-
ment (9, 10, 12), such as Gata2, Foxc2, Gja4, and Itga9 (Figure 
4A). Hdac3Cdh5KO lymphatic vessels had endothelial marker gene 
transcript expression levels similar to those observed in controls 
(Supplemental Figure 7A). Loss of Hdac3 in mesenteric lymphatic 
endothelium also resulted in reduced Prox1 expression (Figure 
4B). Consistent with this observation, we found that Hdac3Lyve1KO 
lymphatic vessels had downregulated expression of Gata2 and 
Foxc2 (Figure 4C). Using laser-capture microdissection (LCMD), 
we collected lymphovenous valves from serial coronal sections of 
E13.5 murine embryos (Supplemental Figure 7, B–D). Hdac3TekKO 
lymphovenous valves revealed similar expression levels of endo-
thelial marker gene transcripts (Supplemental Figure 7D), but 
downregulation of Gata2, Foxc2, Gja4, and Itga9 transcripts, com-
pared with expression levels in controls (Figure 4D). Consistent 
with this observation, IHC revealed reduced expression of Gata2, 
Foxc2, and Prox1 in the developing Hdac3TekKO lymphovenous 
valves (Figure 4, E–G).
Hdac3 regulates OSS-mediated activation of the Gata2 intragenic 
enhancer. Lymph flow and OSS upregulate genes required for lym-
phatic valve development including Gata2 (8, 9, 12). Gata2, an 
important transcription factor for blood-lymph separation and 
development of lymphovenous and lymphatic valves, is an upstream 
transcriptional regulator of Foxc2, Prox1, Gja4, and Itga9 (9, 10, 13, 
14). In addition, the Gata2 intragenic enhancer is both sufficient and 
necessary to drive Gata2 expression within LECs (14, 23). Ablation of 
this Gata2 intragenic enhancer in mice is sufficient to reduce Gata2 
expression and phenocopy the endothelial knockout of Gata2 (24). 
Hence, we examined the mechanism by which Hdac3 regulates 
Gata2 expression. To investigate whether Hdac3 regulates Gata2 
expression in response to shear stress, we analyzed LECs cultured 
under static or OSS conditions (Figure 5A). LECs showed upregula-
Figure 6. Tal1, Gata2, and Ets1/2 recruit Hdac3 to the Gata2 intragenic enhancer in response to lymphatic shear stress. (A) ChIP-qPCR analysis of Hdac3 
recruitment to the Gata2 intragenic enhancer was performed in LECs subjected to static conditions or OSS. (B) Schematic model depicting TRANSFAC 
analysis of ENCODE ChIP-seq data sets at the E-box–GATA–ETS element of the Gata2 intragenic enhancer. (C) ChIP–qPCR analysis of Tal1, Gata2, and Ets1/2 
recruitment to the Gata2 intragenic enhancer was performed in LECs. (D and E) Total lysates from pooled LECs subjected to static or OSS conditions were 
immunoprecipitated by IgG or Hdac3 antibody, and Western blot analysis was performed using Tal1, Gata2, or Ets1/2 antibody (D). Total Hdac3 and α-tubulin 
levels are shown as an input control (D). Tal1, Gata2, and Ets1/2 expression was quantified and normalized to total input using ImageJ software (E). (F)  
ChIP–qPCR analysis of Hdac3 recruitment to the Gata2 intragenic enhancer in scrambled shRNA–,  Tal1 shRNA–, Gata2 shRNA–, or Ets1/2 shRNA–infected 
LECs subjected to OSS (n = 3). Data represent the mean ± SEM and are representative of 3 independent experiments. P values were determined by Student’s 
t test (C and F) or by 1-way ANOVA using Sidak’s multiple comparisons test (A and E). WB, Western blotting. See also Supplemental Figure 10.
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tions encompass the evolutionarily conserved E-box–GATA com-
posite element and ETS motif, respectively (Supplemental Figure 
9). To test the transcriptional activity of this Gata2 intragenic 
enhancer in response to OSS, we generated luciferase reporter 
vectors containing the WT murine Gata2 intragenic enhancer, 
the c.1017+512del28 variant lacking its E-box element, and the 
c.1017+572C>T variant abolishing the ETS motif (Figure 5C). 
OSS increased transcriptional activity of the WT Gata2 intragenic 
enhancer within LECs (Figure 5D). In contrast, OSS failed to 
induce either mutant reporter, suggesting that the E-box–GATA 
composite element and the ETS motif are both required for 
transcriptional activation of the GATA2 intragenic enhancer in 
response to OSS (Figure 5D). Importantly, loss of Hdac3 abolished 
OSS-dependent transcriptional activation of the Gata2 intragenic 
enhancer reporter within LECs (Figure 5E).
Tal1, Gata2, and Ets1/2 recruit Hdac3 to the Gata2 intragenic 
enhancer in a shear stress–dependent manner. To investigate the 
mechanisms by which Hdac3 regulates the Gata2 intragenic 
enhancer, we determined enrichment of Hdac3 at the Gata2 intra-
genic enhancer region in LECs cultured under static or OSS con-
ditions. Hdac3 occupancy at the Gata2 intragenic enhancer was 
tion of Gata2, Foxc2, and Gja4 in response to OSS, and Hdac3 knock-
down abolished this effect (Figure 5B and Supplemental Figure 
8A). Catalytically inactive enzymes are frequently present in most 
enzyme families including HDACs (54). The biological functions 
of these pseudoenzymes remain largely unknown. To determine 
whether deacetylase activity or chromatin recruitment of Hdac3 is 
required to regulate Gata2 expression in response to OSS, we over-
expressed 2 different mutant forms of human HDAC3 in Hdac3- 
deficient LECs. The first mutant, HDAC3HEBI, exhibits no enzymatic 
activity or chromatin recruitment, while the second mutant, HDA-
C3H134A, H135A, lacks enzymatic activity but has preserved chromatin 
recruitment (40, 55). Flag-tagged WT and mutant HDAC3 plasmids 
showed similar levels of expression within LECs (Supplemental Fig-
ure 8B). Expression of either WT Hdac3 or HDAC3H134A, H135A rescued 
Gata2 expression, whereas HDAC3HEBI expression failed to do so 
(Figure 5B). These data indicate that Hdac3 functions in a chromatin- 
dependent, but deacetylase-independent, manner to regulate Gata2 
expression within LECs in response to OSS.
The intron 5 168-bp GATA2 intragenic enhancer region is 
highly conserved (Supplemental Figure 9). Importantly, both the 
c.1017+512del28 deletion region and the c.1017+572C>T muta-
Figure 7. Hdac3 recruits EP300 to the Gata2 intragenic enhancer in response to lymphatic shear stress. (A and B) ChIP–qPCR analysis of H3K27 acetylation 
(A) and EP300 recruitment (B) to the Gata2 intragenic enhancer in scrambled shRNA– or Hdac3 shRNA–infected LECs subjected to static or OSS conditions. 
(C and D) Total lysates from pooled LECs subjected to static or OSS conditions were immunoprecipitated by IgG or EP300 antibody, and Western blot analysis 
was performed using Hdac3 antibody (C). Total Hdac3 and α-tubulin levels are shown as input controls. Hdac3 expression was quantified and normalized to 
total input using ImageJ software (n = 3) (D). (E) Transcripts for Gata2 were detected by ChIP-qPCR in scrambled shRNA– or EP300-shRNA–infected LECs 
subjected to static or OSS conditions. (F) In response to OSS, the transcription factors Tal1, Gata2, and Ets1/2 recruit Hdac3 to the Gata2 intragenic enhancer, 
which in turn recruits EP300 to promote Gata2 expression. In LECs lacking Hdac3, OSS failed to promote EP300 recruitment to the Gata2 intragenic enhancer, 
histone H3 Lys-27 acetylation, and, thereby, Gata2 expression. Data represent the mean ± SEM and are representative of 3 independent experiments. P values 
were determined by Student’s t test (E) or by 1-way ANOVA with Sidak’s multiple comparisons test (A, B, and D). See also Supplemental Figure 10.
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these results suggest a unique function of Hdac3 to mediate blood-
lymph separation during development.
To our knowledge, this is the first report of a histone-modifying 
enzyme regulating separation of the blood and lymphatic vascular 
systems. Recent studies revealed that platelets and podoplanin (an 
LEC receptor) cooperate to prevent blood from entering the lym-
phatic system at the lymphovenous valve (4, 56–60). However, 
we found that ablation of Hdac3 in platelets caused no defects in 
blood-lymph separation (Supplemental Figure 4, A–S), suggesting 
that Hdac3 functions specifically within LECs. Here, we show that 
Hdac3 ablation in LECs prior to lymphovenous valve formation 
(Hdac3TekKO) resulted in a failure of blood-lymph separation at E12.5 
and lethality as early as E13.5 (Supplemental Figure 5 and Supple-
mental Tables 1 and 2). Similarly, complete loss of Hdac3 in LECs 
after lymphovenous valve formation (Hdac3Cdh5KO or Hdac3Lyve1KO) 
led to a failure of blood-lymph separation soon after birth (Figure 
1, B, C, and E–I), followed by complete neonatal lethality (Supple-
mental Tables 3 and 4). These alternative genetic approaches reveal 
that the timing of lethality in mice lacking LEC Hdac3 coincides 
with lymphovenous valve dysfunction and failure of blood-lymph 
separation. However, Hdac3-deficient lymphovenous valves and 
lymphatic vessels showed similar podoplanin expression levels 
compared with levels detected in controls (Figure 2F and Supple-
mental Figure 7, A and D).
These results raise an interesting question: How does ubiqui-
tously expressed Hdac3 function in a LEC-specific manner during 
development? Lacking intrinsic DNA-binding capacity, Hdac3 
must be recruited to the chromatin via its interaction with mul-
tiple protein nuclear complexes, transcription factors, and cofac-
tors (32). Emerging data from genome-wide mapping reveal that 
approximately 60% of Hdac3 occupies intragenic and intergenic 
regions including those marked by H3K27ac (43–47). This distri-
bution suggests enhancer-specific functions for Hdac3. Enhancers 
recruit a multitude of protein complexes to orchestrate gene 
expression in a temporal, spatial, or cell type–specific manner 
(28). The GATA2 intragenic enhancer is both sufficient and nec-
essary to drive GATA2 expression in LECs (14, 23). Our findings 
support a model in which Hdac3 functions in concert with EP300 
to activate, rather than repress, the Gata2 intragenic enhancer 
and thereby establish a specific transcriptional program for LECs. 
This model challenges long-held assumptions that HDACs replace 
HATs to promote both histone deacetylation and repression of 
transcription. Taken together, our findings warrant further inves-
tigation of the extent, if any, to which the intragenic and intergen-
ic occupancy of HDACs contributes to the regulation of enhancer 
functions that modulate gene expression.
Our finding that HDAC3 contributes to the function of the 
GATA2 intragenic enhancer dovetails with recent GWAS reveal-
ing that the majority of genetic variants or mutations associated 
with human diseases map to the noncoding elements in the 
genome (61). A substantial fraction of such mutations are thought 
to disrupt enhancer elements to alter gene expression and cause 
disease; however, only a few examples have been identified (62). 
Consistent with this notion, patients with c.1017+512del28 dele-
tion or a c.1017+572C>T point mutation within the evolutionarily 
conserved GATA2 intragenic enhancer (divergence ~350 million 
years ago) have lymphedema and significantly reduced GATA2 
increased under OSS compared with that observed under static 
conditions, suggesting that lymphatic flow regulates the recruit-
ment of Hdac3 to chromatin (Figure 6A). TRANSFAC (TRAN-
Scription FACtor database; http://genexplain.com/transfac/) 
analysis of ENCODE (Encyclopedia of DNA Elements; https://
www.encodeproject.org/) ChIP-sequencing (ChIP-seq) data sets 
suggested a composite occupancy of the transcription factors 
Tal1, Gata2, and Ets1/2 at the E-box–GATA–ETS element of the 
Gata2 intragenic enhancer (Figure 6B). ChIP–quantitative PCR 
(ChIP-qPCR) analysis confirmed enrichment of Tal1, Gata2, and 
Ets1/2 at the Gata2 intragenic enhancer region in LECs under static 
conditions (Figure 6C). To test the physical interaction of Hdac3 
with Tal1, Gata2, or Ets1/2, we performed immunoprecipitation 
of endogenous Hdac3 protein from LECs cultured under static or 
OSS conditions, followed by immunoblotting for Tal1, Gata2, or 
Ets1/2. We found that OSS induced a physical interaction between 
Hdac3 and Tal1, Gata2, or Ets1/2 in LECs (Figure 6, D and E). Nota-
bly, total expression of Hdac3 protein and Tal1 and Ets1 transcripts 
remained unchanged in LECs in response to OSS (Figure 6D and 
Supplemental Figure 10A). Loss of Tal1, Gata2, or Ets1/2 abolished 
OSS-dependent recruitment of Hdac3 to the Gata2 intragenic 
enhancer in LECs (Figure 6F and Supplemental Figure 10B). LECs 
expressing Tal1, Gata2, or Ets1/2 shRNAs showed similar expres-
sion levels of Hdac3 transcripts (Supplemental Figure 10C).
Hdac3 recruits EP300 to the Gata2 intragenic enhancer to pro-
mote Gata2 transcription in response to OSS. To investigate how 
Hdac3 regulates the activation of the Gata2 intragenic enhancer 
in response to shear stress, we determined the enrichment of 
H3K27ac and EP300 at the Gata2 intragenic enhancer in WT and 
Hdac3-deficient LECs cultured under static or OSS conditions. 
LECs showed enrichment of H3K27ac and EP300 in response to 
OSS, and this enrichment was abolished by Hdac3 knockdown 
(Figure 7, A and B, and Supplemental Figure 10B). We observed that 
Ep300 transcript expression levels remained unchanged in LECs 
in response to OSS (Supplemental Figure 10A). To test the physical 
interaction of Hdac3 and EP300, we performed immunoprecip-
itation of endogenous EP300 protein from LECs cultured under 
static or OSS conditions, followed by immunoblotting for Hdac3. 
OSS induced physical interaction between Hdac3 and EP300 in 
LECs (Figure 7, C and D). Taken together, these results suggest that 
Hdac3 recruits EP300 to the Gata2 intragenic enhancer in response 
to OSS. By contrast, EP300-deficient LECs failed to demonstrate 
transcriptional activation of Gata2 in response to OSS (Figure 7E 
and Supplemental Figure 10B). LECs expressing Tal1, Gata2, or 
Ets1/2 shRNAs showed similar expression levels of Ep300 tran-
scripts (Supplemental Figure 10C). These data suggest that EP300 
recruitment to the Gata2 intragenic enhancer is important for lym-
phatic flow–dependent Gata2 expression (Figure 7F).
Discussion
This study reveals a unique, unexpected, and nonredundant role 
of Hdac3 as a key regulator of blood-lymph separation during 
development. Our results demonstrate that endothelial inactiva-
tion of ubiquitously expressed Hdac3, but not Hdac1 or Hdac2, in 
mice causes embryonic lethality, failure of blood-lymph separa-
tion, lymphedema, and defects in both lymphatic and lymphove-
nous valves. Despite the sequence homology among class I Hdacs, 
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reduced expression of Foxc2 and Prox1 within developing murine 
lymphovenous valves (10, 56). In addition, embryos lacking lym-
phatic Hdac3 or Gata2 have dysplastic mesenteric lymphatic ves-
sels with fewer and disorganized valve-forming territories (10). 
Furthermore, Hdac3 or Gata2 ablation in blood endothelial cells 
causes failure of blood-lymph separation in murine embryos 
between E12.5 and E13.5 (10, 56). Interestingly, Prox1-CreERT2–
mediated inducible Gata2 ablation in lymphatic vasculature at 
E10.5, prior to lymphovenous valve formation, recapitulates this 
phenotype at E13.5 (10). In contrast, Lyve1-Cre–mediated Hdac3 
deletion in lymphatic vasculature causes blood-lymph separation 
failure between E17.5 and P0 (Figure 1, C and I, and Supplemen-
tal Figure 1G). Pan-endothelial Cre-expressing mice (Tek-Cre 
mice) show recombinase activity in LEC precursors at E10.5, 
prior to lymphovenous valve formation (68). However, Lyve1- 
Cre–expressing embryos reveal fully penetrant recombinase 
activity within lymphovenous valves at E14.5, after lymphovenous 
valve formation (69). These alternative genetic approaches reveal 
that failure of blood-lymph separation due to lymphovenous valve 
defects corresponds with the timing of endothelial Hdac3 ablation 
in both Lyve1-Cre and Tek-Cre mice.
Overall, our study suggests that enhancer-specific epigene-
tic signatures are functional components of mechano-induced 
transcriptional responses during lymphatic valve development. 
Future studies will define the precise mechanotransduction and 
mechanosensory pathways that integrate extracellular signaling at 
enhancers during lymphatic vascular development.
Methods
Mice. Tek-Cre (51), Cdh5-Cre (50), Lyve1-Cre (52), Pf4-iCre (codon- 
improved Cre recombinase) (53), and Gt(ROSA)26Sor (70) reporter mice 
were obtained from The Jackson Laboratory. Hdac1fl/fl (71), Hdac2fl/fl 
(72), and Hdac3fl/fl (47) mice have been previously described.
Antibodies and reagents. Detailed antibody information is provided 
in Supplemental Table 6. Biotinylated secondary antibodies, VECTA-
SHIELD mounting medium, the VECTASTAIN Elite ABC Kit, and 
the DAB Peroxidase Substrate Kit were purchased from Vector Lab-
oratories. Harris modified hematoxylin, eosin Y, ethanol, methanol, 
chloroform, glacial acetic acid, xylenes, paraformaldehyde, paraffin, 
potassium ferricyanide, potassium ferrocyanide, and deoxycholic acid 
were purchased from Thermo Fisher Scientific. X-Gal was purchased 
from Five Prime Therapeutics. Linear polyethylenamine (PEI) was pur-
chased from Polysciences. The RNeasy Mini Kit and GST bead slurry 
were purchased from QIAGEN. Power SYBR Green PCR Master Mix, a 
Superscript First Strand Synthesis Kit, a TOPO-TA Cloning Kit, DMEM 
high-glucose with NA pyruvate, penicillin-streptomycin, horse serum, 
a CellsDirect One-Step qRT-PCR Kit, insulin-transferrin-selenium 
(ITS), epoxy M-450 dynabeads, and TRIzol were purchased from Life 
Technologies (Thermo Fisher Scientific). iScript Reverse Transcrip-
tion Supermix was purchased from Bio-Rad. Passive lysis buffer and 
a dual-luciferase reporter assay kit were purchased from Promega. 
BALB/c murine primary LECs, basal medium, and complete mouse 
endothelial cell medium were purchased from Cell Biologics. FBS, 
donkey serum, gelatin, rabbit serum, Evans blue dye, protease inhib-
itor mixture, and magnetic anti-Flag beads were purchased from Mil-
liporeSigma. Agarose IgG and IgA bead slurry were purchased from 
Santa Cruz Biotechnology and Life Technologies (Thermo Fisher Sci-
expression (20–22, 63). The present study takes this scenario one 
step further by revealing that Hdac3 functions as an important 
epigenetic switch to promote enhanceosome complex forma-
tion at a deeply conserved Gata2 intragenic enhancer element in 
response to OSS. Disruption of the E-box or ETS motif nullifies 
Hdac3-mediated induction of Gata2 expression, suggesting that 
perturbation of these regions disrupts the assembly of the Tal1-
Gata2-Ets1/2-Hdac3-Ep300 enhanceosome in developing lym-
phatic endothelium. These results suggest a mechanism by which 
c.107+512del28 or c.107+572C>T mutations cause lymphedema. 
This model supports the hypothesis that enhanceosomes function 
as a transcription activation switch for developmentally important 
transcription factors in response to intrinsic or extrinsic signaling 
cues (64, 65). While we do not yet fully understand the nature of 
the enhancer elements in the developing lymphatic system, these 
studies broaden the role of enhanceosomes at deeply conserved 
enhancer elements in lymphatic valve development.
Here, we highlight the integrated nature of extracellular forces 
and epigenetic signatures at the enhancer elements. Our data 
show that OSS promotes assembly of the enhanceosome com-
plex containing the transcription factors Gata2, Tal1, Ets1/2 and 
the histone-modifying enzymes Hdac3 and EP300 at the Gata2 
intragenic enhancer–specific E-box–GATA–ETS composite ele-
ment. Concentrated clusters of transcription factor recognition 
motifs within the composite element facilitate direct cooperative 
binding of multiple transcription factors prior to enhancer activa-
tion (64). Such “priming” of enhancer elements allows additional 
recruitment of both cofactors and effectors of signal transduction 
pathways to integrate intrinsic and extrinsic signaling cues during 
key stages of development (27). We propose that cooperative 
interactions among Gata2, Tal1, and Ets1/2 at the E-box–GATA–
ETS composite element lead to priming of the Gata2 intragenic 
enhancer. OSS-mediated mechanotransduction promotes recruit-
ment of Hdac3 and thereby EP300 at the primed Gata2 intragenic 
enhancer to modify the epigenetic signature, which in turn rapidly 
activates Gata2 transcription (Figure 7F). In line with this concept, 
developing LECs subjected to OSS exhibit robust upregulation of 
Gata2, which is important for lymphatic valve development (9, 
10). In addition, murine embryos lacking endothelial Tal1 display 
edema, blood-filled superficial vessels, and complete lethality at 
E14.5 (66). Global loss of both Ets1 and Ets2 in murine embryos 
also causes edema, blood-filled dilated superficial vessels, pooling 
of blood in the jugular region, and complete lethality at E15.5 (67). 
These phenotypes appear very similar to those in murine embryos 
lacking endothelial Hdac3. Hence, our data warrant a reexamina-
tion of Tal1-knockout and Ets1/2-knockout phenotypes to deter-
mine whether Tal1 and Ets1/2 regulate blood-lymph separation 
and lymphatic valve development.
While the transcriptional regulators of Gata2 are defined, the 
epigenetic modifiers remain unknown. Our data identify Hdac3 
as a positive transcriptional regulator of Gata2. Consistent with 
this notion, embryos lacking endothelial Hdac3 (our observations) 
or Gata2 (10, 56) show highly similar phenotypes. For instance, 
endothelial ablation of Hdac3 causes shortened lymphovenous 
valve leaflets with defective perpendicular alignment to the flow 
direction, similar to those seen in murine embryos lacking endo-
thelial Gata2 (56). Loss of endothelial Hdac3 or Gata2 also causes 
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and then incubated in β-gal staining solution (5 mM potassium ferri-
cyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2, 0.04% NP-40, 
0.01% deoxycholate, and 0.1% X-gal substrate in 1× PBS) for 48 to 72 
hours at 37°C in the dark. Embryos were then washed 3 times for 20 
minutes each in 1× PBS at room temperature and fixed overnight in 
4% paraformaldehyde.
IHC. IHC was performed as we previously described (40). Briefly, 
slides with sections were deparaffinized and immersed in sodium 
citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6) or 
R-buffer A (pH 6; Electron Microscopy Sciences) and placed in a 
2100 Antigen Retriever (Aptum Biologics) for heat-induced antigen 
re trieval. IHC was conducted using a VECTASTAIN Elite ABC Kit and a 
DAB Peroxidase Substrate Kit (both from Vector Laboratories) accord-
ing to the manufacturer’s guidelines. Sections were incubated with pri-
mary antibodies overnight at 4°C (Supplemental Table 6). Biotinylat-
ed universal pan-specific antibody (1:62.5) (horse anti-mouse/rabbit/
goat IgG); biotinylated universal antibody (horse anti-mouse/rabbit 
IgG); or biotinylated rabbit anti-rat IgG antibody (1:62.5) (all from Vec-
tor Laboratories) were used as secondary antibodies for 1 hour at 25°C 
according to the manufacturer’s instructions. For counterstaining, 
slides were rinsed and then incubated with 30% hematoxylin for 30 
seconds after DAB development. All slides were ethanol dehydrated, 
cleared with xylenes, and mounted with VECTASHIELD mounting 
medium. For immunofluorescence staining, after antigen retrieval, 
sections were blocked in 10% donkey serum and 0.3% Triton X-100 
in PBS for 1 hour at room temperature. Sections were then washed in 
PBS and coincubated with primary antibodies in 10% donkey serum 
and PBS overnight at 4°C (Supplemental Table 6). Finally, slides were 
washed in PBS, incubated in Alexa Fluor 488– or 546/568–conjugated 
secondary antibodies (1:500) with Hoechst (1:1,000) for 1 hour at 
room temperature, rinsed in PBS, and mounted with VECTASHIELD 
mounting medium.
Cell culture, transient transfection, lentiviral infection, and lucifer-
ase assay. Murine primary LECs were maintained in complete mouse 
endothelial cell medium in a 37°C incubator with 5% CO2 according 
to the manufacturer’s protocol (Cell Biologics). All experiments were 
conducted using passage 3–6 LECs. HEK293T cells were maintained 
in DMEM with 10% FBS, 100 mg/ml penicillin, and 100 mM/ml strep-
tomycin in a 37°C incubator with 5% CO2. Subconfluent HEK293T 
cells were transfected in 100-mm plates with 5 μg lentiviral plasmid 
expressing the relevant cDNA or shRNA, 5 μg pCMV-dR8.2, 2.5 μg 
pCMV-VSVG, and 5 μl PEI, in 10 ml of 2% FBS media. Media were 
changed to fresh FBS media (10 ml of 1%) 24 hours after transfection. 
Supernatant media were collected 24 hours later and filtered through 
a 40-μm cell strainer. Murine primary LECs were infected with fresh- 
filtered viral media supplemented with 10 μg/ml polybrene reagent. 
Murine primary LECs were transiently transfected using a PEI-based 
transfection protocol (39, 40, 74, 75). Each well of a 6-well plate con-
taining subconfluent (~60% confluent) LECs was transfected with a 
total of 1 μg plasmid DNA, including 0.5 μg WT or c.1017+512del28, or 
the c.1017+572C>T Gata2 intragenic enhancer pGL3-promoter lucifer-
ase vector, with or without 0.5 μg Hdac3 shRNA–expressing vector and 
2 μl PEI (1 mg/ml in double-distilled H2O, pH 7.0), in 2 ml complete 
mouse endothelial cell medium. The PEI-DNA complex was incubated 
at room temperature for 20 minute before adding it to LECs in a 
drop-wise manner. The DNA amount was maintained constant using 
pcDNA3.1(-) DNA. LECs were trypsinized and reseeded to a μ-Slide VI 
entific). μ-Slide VI 0.4 Luer was purchased from Ibidi. The EZ-ChIP 
Assay Kit was purchased from MilliporeSigma. The RecoverAll Total 
Nucleic Acid Isolation Kit was purchased from Thermo Fisher Scientific. 
The CellAmp Whole Transcriptome Amplification Kit and the Takara 
DNA Ligation Kit were purchased from Takara. Membrane slides and 
isolation caps were purchased from Molecular Machines & Industries.
Plasmids. WT, c.1017+512del28, and c.1017+572C>T Gata2 intra-
genic enhancer fragments with flanking restriction enzyme sites were 
purchased as MiniGenes cloned into a pIDTSMART-AMP vector from 
Integrated DNA Technologies. The enhancer fragments were digested 
with MluI and XhoI, gel purified, and cloned into the pGL3-Promoter 
Luciferase Vector (Promega). All plasmids were verified by restriction 
analyses and sequencing (Eurofins MWG Operon). Lentiviral plas-
mids expressing Hdac3 shRNA, EP300 shRNA, Tal1 shRNA, Ets1/2 
shRNA, Gata2 shRNA, and scrambled shRNA controls were obtained 
from the University of Massachusetts shRNA Core Facility. Plasmids 
expressing human GFP, HDAC3, HDAC3HEBI, and HDAC3H134A, H135A 
have been previously described (40, 55).
Imaging. Images of dissected embryos, mice, and tissue sample 
were captured using a Leica MZ10 F fluorescence stereomicroscope 
equipped with a ×0.7 C-mount, Achromat 1.0 × 90 mm objective, a 
SOLA light engine, a DS-Fi1 color camera (Nikon), and NIS-Elements 
Basic Research software (Nikon). Stained section images were cap-
tured using a Nikon Eclipse 80i microscope equipped with CFI Plan 
Fluor ×4/×10/×20/×40 objective lenses, a SOLA light engine (Lumen-
cor), a DS-Fi1 color camera, and NIS-Elements Basic Research soft-
ware. Whole-mount immunostained images were captured using a 
Zeiss LSM710 confocal scanning microscope equipped with a W Plan- 
Apochromat ×20/1.0 DIC D = 0.17 M27 70-mm objective lens as previ-
ously described (73). Whole-mount immunostained mesenteric vessels 
were flat mounted onto histobond glass slides using VECTASHIELD 
mounting medium for immunofluorescence and imaged using a Nikon 
Eclipse 80i microscope or a Leica TCS SP5 II Laser Scanning Confocal 
microscope. Alexa Fluor 488 and 568 were simultaneously excited at 
488 nm and 561 nm with confocal lasers, respectively. Emissions were 
split by an MBS 488/561/633 beam splitter and captured with 2 detec-
tion ranges (ch1: 493–536 nm, ch2: 576–685 nm). For nuclear staining, 
Hoechst was excited using a Chameleon Ti:Sapphire pulse laser (755 nm) 
(Coherent Inc.) and was emission detected at 387 to 486 nm. Image stacks 
of vertical projections were assembled using ImageJ software (NIH).
Histology. Embryos and tissues samples were fixed in 2% parafor-
maldehyde at 4°C overnight, ethanol dehydrated, embedded in paraf-
fin, and sectioned at 6- to 8-μm thickness using a Leica fully motorized 
rotary microtome.
H&E staining. Formalin-fixed, paraffin-embedded tissue sections 
were deparaffinized in xylene and rehydrated through an ethanol gradi-
ent, followed by 2-minute Harris modified hematoxylin and 30-second 
eosin-Y staining. Slides were dehydrated with ethanol, cleared with 
xylene, and mounted with VECTASHIELD mounting medium.
In vitro OSS experiments. Transiently transfected or infected 
murine primary LECs were seeded at confluence on μ-Slide VI 0.4 
Luer, cultured for 24 hours, and subjected to OSS (4 dynes/cm2, 4 Hz) 
in a parallel-plate flow chamber system (Ibidi Pump System; Ibidi) or 
under static conditions for 48 hours.
β-Gal staining. Embryos were dissected and placed in ice-cold 
1× PBS and then fixed in 4% paraformaldehyde for 1 hour at 4°C. 
Embryos were washed in 1× PBS for 30 minutes at room temperature 
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PCR Master Mix as previously described (40). Signals were normal-
ized to corresponding GAPDH controls and are represented as relative 
expression ratios of the experimental samples relative to controls.
Whole-mount IHC. Mesentery tissues from P5 mice were dissect-
ed, fixed in 4% paraformaldehyde overnight at 4°C, washed in 1× PBS 
twice at 4°C for 30 minutes, and dehydrated through a methanol gradi-
ent. The samples were then incubated with antibodies against Vegfr3 
(1:200) and Hdac3 (1:50) or Prox1 (1:100) overnight at 4°C. Finally, tis-
sue samples were washed in PBS, incubated overnight at 4°C in Alexa 
Fluor 488– or 546/568–conjugated secondary antibodies (1:200), with 
or without Hoechst (1:1,000), rinsed in PBS, and then imaged using 
confocal microscopy.
Evans Blue dye lymphangiography. Evans blue dye (50 μl of 1%, 10 
mg/ml), prepared in 1× PBS (pH 7.4), was injected into the left hind 
footpad of anesthetized mice, with the needle pointed in the dorsal 
direction. Fifteen minutes after injection, the mice were euthanized 
and dissected to examine lymphatic vessels, the thoracic duct, and 
lymph nodes of interest.
Platelet count. Approximately 100 μl of blood was drawn from 
each anesthetized P5 pup via intracardiac puncture and collected in 
200 μl citrate-phosphate-dextrose (CPD) buffer (16 mM citric acid 
[anhydrous], 102 mM trisodium citrate, 18.5 mM NaH2PO4, 142 mM 
D-glucose, pH 7.4) as described previously (76). Platelet counts were 
obtained and calculated using an automated cell counter (Beckman 
Coulter; Ac.T 8).
Immunoprecipitation and Western blot analysis. Samples were 
homogenized in immunoprecipitation buffer (50 mM Tris-HCl pH 
8.0, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA, and 1 mM DTT) 
containing 1 mM PMSF and a protease inhibitor mixture. The homog-
enized samples were sonicated using a Branson 250 Digital Sonifier 
with 1-second-on and 1-second-off pulses at 40% power amplitude 
for 15 seconds. Precleared lysates were incubated with the relevant 
primary antibody–conjugated magnetic beads for 16 hours at 4°C. 
Immune complexes were collected, washed 4 times with immuno-
precipitation buffer, and applied to 4%–12% SDS-polyacrylamide gels 
for Western blot analysis before transferring to PVDF membranes. 
Primary antibodies against HDAC3 (1:1,000), Tal1 (1:1,000), Gata2 
(1:1,000), and Ets1/2 (1:1,000) were used and visualized by chemilu-
minescence using HRP-conjugated secondary antibodies. Blots were 
probed with α-tubulin (1:1,000) for the loading control.
Statistics. Statistical significance was determined using a 2-tailed 
Student’s t test, a χ2 test, or a 1-way ANOVA with Sidak’s multiple com-
parisons test (GraphPad Prism 7.0; GraphPad Software). A P value of 
less than 0.05 was considered significant.
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emies Press, 2011). The IACUC of the University of Massachusetts 
Medical School approved all animal use protocols.
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